MAP4K2: Key Regulator of Rho GTPase Complex and Potential Drug Target/Biomarker

Target Name: MAP4K2

NCBI ID: G5871

MAP4K2

MAP4K2: Key Regulator of Rho GTPase Complex and Potential Drug Target/Biomarker

MAP4K2 (Mammalian Arginine-Protein Ligation 2) is a protein that plays a crucial role in cellular signaling pathways. It is a key regulator of the Rho GTPase complex, which is involved in many cellular processes, including cell division, migration, and invasion. In addition to its role in cell signaling, MAP4K2 has also been shown to have potential as a drug target and biomarker.

The Rho GTPase complex is a protein-protein interaction network that plays a central role in regulating various cellular processes. The complex consists of several subunits, including a protein that binds to arginine residues on the target protein and another protein that binds to the protein's C-terminus. When the two subunits bind, it activates the Rho GTPase enzyme, which adds a GTP molecule to the protein, leading to changes in the protein's structure and function.

MAP4K2 is a key regulator of the Rho GTPase complex. It is a 21-kDa protein that contains an N-terminal arginine-containing domain, a catalytic C-terminus, and a C-terminal hypervariable region (HVR). The N-terminal domain is responsible for interacting with the Rho GTPase protein, while the C-terminus is involved in the formation of the complex.

MAP4K2 has been shown to play a role in many cellular processes, including cell signaling, cell division, and migration. For example, MAP4K2 has been shown to regulate the formation of mitotic spindles, which are important for cell division. In addition, MAP4K2 has also been shown to play a role in cell migration, as it has been shown to regulate the movement of neurons in the brain.

In addition to its role in cell signaling, MAP4K2 has also been shown to have potential as a drug target and biomarker. For example, MAP4K2 has been shown to be a promising drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This is because its activity as a regulator of the Rho GTPase complex makes it a potential target for small molecules that can inhibit the activity of the enzyme.

One of the most promising compounds that has been shown to interact with MAP4K2 is the drug pyridostigmine. Pyridostigmine is a neurotransmitter that is involved in many cellular processes, including neurotransmission and synaptic plasticity. It has been shown to interact with MAP4K2 and inhibit its activity, which suggests that it may be a useful drug for the treatment of various neurological and psychiatric disorders.

In addition to its potential as a drug target, MAP4K2 has also been shown to be a valuable biomarker for several diseases. For example, it has been shown to be a potential biomarker for neurodegenerative diseases, as its levels have been shown to be affected by the progression of these diseases. It has also been shown to be a potential biomarker for cancer, as its levels have been shown to be affected by the development and progression of cancer.

In conclusion, MAP4K2 is a protein that plays a crucial role in cellular signaling pathways. It is a key regulator of the Rho GTPase complex and has been shown to play a role in many cellular processes, including cell signaling, cell division, and migration. In addition to its role in cell signaling, MAP4K2 has also been shown to have potential as a drug target and biomarker. The use of small molecules that can inhibit the activity of the enzyme may be a promising strategy for the treatment of various diseases.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase Kinase 2

Functions: Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion

The "MAP4K2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP4K2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets